Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial

Table 3 Identification of the factors contributing to LDA achievement after baricitinib or tofacitinib treatment

	Baricitinib Univariate analysis		Multivariate analysis		Tofacitinib Univariate analysis		Multivariate analysis
	OR (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value	OR (95%CI)	P-value
Age	1.00–1.11	0.04	1.01–1.17	0.04	0.96–1.04	0.94
Sex	#				#
Disease duration	0.97–1.00	0.08			0.99–1.01	0.87
WBC	0.42–0.95	0.03	0.26–5.21	0.83	0.63–1.03	0.08
NEU	0.38–0.90	0.02	0.09–1.94	0.27	0.51–0.91	0.008	0.54–1.08	0.13
LYM	0.43–6.27	0.47			0.88–6.62	0.09
HB	0.95–1.06	0.80			#
PLT	0.98–1.00	0.015	0.98–1.00	0.10	0.99–1.00	0.09
ESR (mm/h)	#				0.93–0.98	0.001	0.93–0.99	0.01
RF (IU/mL)	0.98–1.00	0.14			0.99–1.00	0.13

#Due to P-value being < 0.05 in the Hosmer–Lemeshow test, logistic regression analysis was not performed
LDA: low disease activity, WBC: white blood cell, NEU: neutrophil, LYM: lymphocyte, HGB: hemoglobin, PLT: blood platelet, and RF: rheumatoid arthritis

ISSN: 2523-3106